|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 254.30 EUR | +0.55% |
|
-2.20% | +6.41% |
| 01-21 | Ocular Therapeutix, Inc. Appoints David W. Robinson As Global Chief Commercial Officer | CI |
| 01-15 | UCB SA Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 07:30 AM |
| Capitalization | 48.05B 56.2B 44.6B 41.83B 77.61B 5,148B 83.1B 512B 203B 2,433B 211B 206B 8,887B | P/E ratio 2025 * |
42x | P/E ratio 2026 * | 30.3x |
|---|---|---|---|---|---|
| Enterprise value | 48.5B 56.72B 45.02B 42.22B 78.33B 5,196B 83.88B 517B 204B 2,456B 213B 208B 8,970B | EV / Sales 2025 * |
6.67x | EV / Sales 2026 * | 5.6x |
| Free-Float |
61.3% | Yield 2025 * |
0.56% | Yield 2026 * | 0.58% |
Last Transcript: UCB
| 1 day | +0.40% | ||
| 1 week | -2.20% | ||
| Current month | +6.41% | ||
| 1 month | +6.91% | ||
| 3 months | -0.70% | ||
| 6 months | +46.51% | ||
| Current year | +6.41% |
| 1 week | 250.7 |  | 268.4 |
| 1 month | 232.5 | | 268.4 |
| Current year | 232.5 | | 268.4 |
| 1 year | 129.35 | | 268.4 |
| 3 years | 65.4 | | 268.4 |
| 5 years | 65.4 | | 268.4 |
| 10 years | 54.84 | | 268.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 59 | 01/07/2020 |
Antje Witte
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.55% | -2.20% | +38.74% | +229.65% | 56.2B | |
| +2.12% | -0.64% | +8.95% | +3.79% | 76.88B | |
| -2.45% | +87.30% | +87.30% | +87.30% | 59.21B | |
| +1.31% | +1.79% | -33.98% | -40.21% | 57.42B | |
| +4.38% | +1.95% | +22.44% | -39.59% | 25.32B | |
| +2.00% | -1.21% | +42.47% | +25.81% | 20.55B | |
| -1.51% | -9.17% | +159.58% | +75.87% | 18.4B | |
| -22.35% | -21.78% | +17.27% | +998.53% | 13.64B | |
| +15.84% | +22.75% | +38.79% | -74.32% | 19.46B | |
| +1.24% | +0.32% | +116.60% | +827.05% | 15.06B | |
| Average | +0.07% | -1.08% | +49.82% | +209.39% | 36.21B | |
| Weighted average by Cap. | +0.71% | -0.92% | +36.47% | +114.90% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 7.27B 8.5B 6.75B 6.33B 11.74B 779B 12.57B 77.45B 30.65B 368B 31.89B 31.23B 1,345B | 8.39B 9.82B 7.79B 7.31B 13.56B 899B 14.52B 89.42B 35.39B 425B 36.81B 36.06B 1,552B |
| Net income | 1.15B 1.35B 1.07B 1.01B 1.86B 124B 2B 12.3B 4.87B 58.46B 5.06B 4.96B 214B | 1.57B 1.83B 1.45B 1.36B 2.53B 168B 2.71B 16.67B 6.6B 79.25B 6.86B 6.72B 289B |
| Net Debt | 448M 524M 416M 390M 724M 48.03B 775M 4.78B 1.89B 22.7B 1.97B 1.93B 82.91B | -1.04B -1.21B -963M -904M -1.68B -111B -1.79B -11.06B -4.38B -52.55B -4.55B -4.46B -192B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/01/26 | 254.30 € | +0.55% | 3,663 |
| 21/01/26 | 252.90 € | -1.37% | 177,969 |
| 20/01/26 | 256.40 € | -0.58% | 192,833 |
| 19/01/26 | 257.90 € | -2.90% | 157,941 |
| 16/01/26 | 265.60 € | +2.35% | 243,249 |
Real-time Euronext Bruxelles, January 22, 2026 at 04:13 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition